GSK Invests £400m in Cambridge R&D Hub, Closing Stevenage Site

After 50 years in Stevenage, GSK is packing up its research headquarters and heading south. The pharmaceutical giant has announced plans to close its Stevenage site and relocate approximately 1,000 staff to a new R&D facility on the Cambridge Biomedical Campus, part of a £400 million investment that also includes upgrading labs in Ware, Hertfordshire.

The move, with a phased relocation and the Stevenage site earmarked for closure in 2029, places GSK squarely in what the company calls "the heart of the UK life sciences Golden Triangle." The stated goal: "accelerate our R&D and help us deliver new, competitive products."

GSK's Strategic Move to Cambridge

The Cambridge Biomedical Campus is already a dense cluster of life sciences activity. More than 22,000 people work there, including staff at AstraZeneca, Addenbrooke's Hospital, Royal Papworth Hospital, and a new Cambridge Cancer Hospital under construction. GSK already has a presence on the campus through collaborations such as the Cambridge Centre for Data-Driven Discovery, the Cambridge-GSK Translational Immunology Collaboration, and the Cambridge-GSK Metabolic Science Collaboration.

Co-location with a major competitor like AstraZeneca, alongside world-class hospital and academic partners, creates a concentrated environment for translational research. For GSK, the logic is proximity to talent, clinical infrastructure, and the kind of cross-institutional collaboration that can shorten the distance between lab discovery and patient treatment.

What the £400m buys

The investment covers three new R&D buildings currently under construction on the Cambridge campus, featuring state-of-the-art labs and infrastructure. GSK says the site will support research in its focus areas: oncology, respiratory, hepatology, vaccines, and HIV. The company will also upgrade its existing R&D laboratories at Ware, Hertfordshire, and move some employees there.

The Stevenage closure marks the end of a five-decade presence in the town. While GSK has not detailed the exact financial impact on its balance sheet or specific pipeline timelines, the scale of the investment signals a long-term commitment to the Cambridge cluster rather than a retreat from UK R&D.

Impact on the UK biotech landscape

The consolidation of GSK's research operations into Cambridge reinforces the city's status as the UK's dominant life sciences hub. For Stevenage, the loss of approximately 1,000 high-skilled jobs is a significant blow, though some employees may relocate to Ware or Cambridge. The broader UK biotech ecosystem will likely see increased competition for talent and lab space in Cambridge, where AstraZeneca and a growing number of startups already operate.

GSK's decision also reflects a wider industry trend: large pharma companies are concentrating R&D in a smaller number of high-density innovation clusters, betting that physical proximity to academic hospitals, data science centres, and other drug developers accelerates the pace of discovery. The Cambridge Biomedical Campus, with its mix of big pharma, NHS hospitals, and academic institutions, offers exactly that density.

Implications for drug development

GSK's R&D focus areas — oncology, respiratory, hepatology, vaccines, and HIV — align with the strengths of the Cambridge cluster. The presence of the Cambridge Cancer Hospital and Addenbrooke's clinical unit means GSK can run early-phase trials and translational studies in closer collaboration with clinicians and patients. The company's existing collaborations in data-driven discovery and immunology provide a foundation for integrating AI and computational biology into its R&D workflow.

Whether the move will meaningfully shorten drug development timelines or improve pipeline success rates remains to be seen. But the strategic bet is clear: put researchers next to clinicians, data scientists, and academic partners, and the odds of turning science into approved therapies improve.

The bigger picture

GSK's relocation is part of a broader reshaping of the UK's life sciences geography. The Golden Triangle — Oxford, Cambridge, and London — continues to attract investment and talent, while other regions risk losing established pharma anchors. For the UK government, which has positioned life sciences as a post-Brexit growth sector, the GSK move is a vote of confidence in the Cambridge cluster, but it also raises questions about regional imbalances in R&D investment.

For GSK, the £400 million bet is about more than real estate. It's an admission that the old model of isolated, suburban R&D campuses is giving way to integrated, urban innovation districts. The company is betting that the Cambridge Biomedical Campus — with its 22,000 life sciences workers, competing and collaborating pharma firms, and adjacent hospitals — will provide the environment needed to deliver the next generation of medicines.

The Stevenage site will close in 2029. By then, GSK expects its new Cambridge labs to be fully operational, and the company's R&D future will be written in the Golden Triangle.